Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 398

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs

Open access
Yokota, Toshifumi, Lu, Qi‐long, Partridge, Terence, Kobayashi, Masanori, Nakamura, Akinori, Takeda, Shińichi, Hoffman, Eric·2009·Annals of Neurology

Abstract

Objective: Duchenne muscular dystrophy (DMD) is caused by the inability to produce dystrophin protein at the myofiber membrane. A method to rescue dystrophin production by antisense oligonucleotides, termed exon‐skipping, has been reported for the mdx mouse and in four DMD patients by local intramuscular injection. We sought to test efficacy and toxicity of intravenous oligonucleotide (morpholino)‐induced exon skipping in the DMD dog model. Methods: We tested a series of antisense drugs singly and as cocktails, both in primary cell culture, and two in vivo delivery methods (intramuscular injection and systemic intravenous injection). The efficiency and efficacy of multiexon skipping (exons 6–9) were tested at the messenger RNA, protein, histological, and clinical levels. Results: Weekly or biweekly systemic intravenous injections with a three‐morpholino cocktail over the course of 5 to 22 weeks induced therapeutic levels of dystrophin expression throughout the body, with an average of about 26% normal levels. This was accompanied by reduced inflammatory signals examined by magnetic resonance imaging and histology, improved or stabilized timed running tests, and clinical symptoms. Blood tests indicated no evidence of toxicity. Interpretation: This is the first report of widespread rescue of dystrophin expression to therapeutic levels in the dog model of DMD. This study also provides a proof of concept for systemic multiexon‐skipping therapy. Use of cocktails of morpholino, as shown here, allows broader application of this approach to a greater proportion of DMD patients (90%) and also offers the prospect of selecting deletions that optimize the functionality of the dystrophin protein. Ann Neurol 2009

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.21627

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 398

Metadata

Authors
Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., & Hoffman, E.
Venue
Annals of Neurology
Publisher
Wiley
Published
2009-03-13
Volume
65
Issue
6
Pages
667-676
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2062442451
Cited by
398
References
29
FWCI
16.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs. https://app.cochat.ai/papers/10.1002/ana.21627
The paper
Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., & Hoffman, E. (2009). Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs. Annals of Neurology. https://doi.org/10.1002/ana.21627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.